 |
|
|
||||||||||||||
 |
|
|
Download the PDF here
Diabetes test gives 5-year disease-prediction window.
2008-Jun-09 — There is an old saying that seems appropriate when describing Tethys Bioscience's (Emeryville, California) PreDX Diabetes Risk Test: Forewarned is forearmed. The company presented clinical results of the test and reported expanding the tests availability during the American Diabetes Association's (Alexandria, Virginia) annual meeting in San Francisco this past week.
The PreDX Diabetes Risk Test serves as a predictive tool that is said by the company to deliver an accurate assessment of an individual's risk of developing Type 2 diabetes within the next five years. The test is performed exclusively by the Tethys Bioscience Clinical Laboratory on routinely collected blood samples.
< Back
Jul 22, 2010
Tethys Raises $33 Million
Tethys Bioscience, Inc., announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan.
Jul 14, 2010
Diabetes Risk, on a Scale of 1 to 10
A new test is transforming the way some doctors diagnose and treat their patients.
(Technology Review)
Jul 1, 2010
PreDx® featured on CBS Interactive's Smartplanet
CBS Interactive smartplanet video segment focuses on the impact of the PreDx® Diabetes Risk Score on the physician and patient.
Jun 24, 2010
Tethys Announces Issuance of Key Patent Relating to PreDx™ Diabetes Risk Score Test
United States Patent and Trademark Office grants patent to Tethys. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)